Jianning Yang

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the <scp>BCL</scp>2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory <scp>CD</scp>20⁺ lymphoid malignancies

Andrew W. Roberts, Ranjana H. Advani, Brad S. Kahl et al. · British Journal of Haematology · 2015 · 98 citations · Full text

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

Matthew S. Davids, John F. Seymour, John F. Gerecitano et al. · Journal of Clinical Oncology · 2014 · 91 citations

Immunology, Pathology, Pharmacotherapy +18

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

James M. Cleary, Caio Max S. Rocha Lima, Herbert I. Hurwitz et al. · Investigational New Drugs · 2014 · 74 citations

Oncology, Solid Tumors, Medicine +6

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Matthew S. Davids, John M. Pagel, Brad S. Kahl et al. · Blood · 2013 · 69 citations

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

Gordana Vlahovic, Vassiliki Karantza, Ding Wang et al. · Investigational New Drugs · 2014 · 59 citations

Oncology, Solid Tumors, Medicine +5